scispace - formally typeset
D

Darwyn Kobasa

Researcher at University of Manitoba

Publications -  61
Citations -  2022

Darwyn Kobasa is an academic researcher from University of Manitoba. The author has contributed to research in topics: Virus & Influenza A virus. The author has an hindex of 18, co-authored 61 publications receiving 1420 citations. Previous affiliations of Darwyn Kobasa include Canadian Science Centre for Human and Animal Health & Public Health Agency of Canada.

Papers
More filters
Journal ArticleDOI

Proteolytic Activation of the 1918 Influenza Virus Hemagglutinin

TL;DR: It is shown that the previously reported 1918 NA-dependent spread of the 1918 influenza virus is a cell line-dependent phenomenon and is not due to plasminogen recruitment by the 1918 NA, and evidence is provided that TMPRSS2 and TMPR SS4 activate the 1918 HA by cleavage and therefore may promote viral spread in lung tissue.
Journal ArticleDOI

Lethal Influenza Virus Infection in Macaques Is Associated with Early Dysregulation of Inflammatory Related Genes

TL;DR: Compared pathology and global gene expression profiles in bronchial tissue from macaques infected with either the reconstructed 1918 pandemic virus or the highly pathogenic avian H5N1 virus A/Vietnam/1203/04 suggest that the severity of disease in 1918 virus-infected macaques is a consequence of the early up-regulation of cell death and inflammatory related genes, in which additive or synergistic effects likely dictate the severityof tissue damage.
Posted ContentDOI

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

TL;DR: The LY-CoV1404 (also known as bebtelovimab) is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient sample, obtained approximately 60 days after symptom onset as mentioned in this paper.
Posted ContentDOI

LY-CoV1404 potently neutralizes SARS-CoV-2 variants

TL;DR: The LY-CoV1404 as discussed by the authors antibody is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient approximately 60 days after symptom onset.
Journal ArticleDOI

Quantitative Proteomic Analyses of Influenza Virus-Infected Cultured Human Lung Cells

TL;DR: Gene ontology and pathway analyses indicated differentially regulated proteins and included those involved in host cell immunity and antigen presentation, cell adhesion, metabolism, protein function, signal transduction, and transcription pathways.